e-Article
Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study.
Document Type
Article
Author
Source
Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p4504-4504, 1p
Subject
Language
ISSN
0732183X